NASDAQ:IPSC Century Therapeutics (IPSC) Stock Price, News & Analysis → 8,788% Return Predicted For THIS Crypto (already up 40% in 6 months) (From Paradigm Press) (Ad) Free IPSC Stock Alerts $4.75 -0.25 (-5.00%) (As of 03/18/2024 ET) Add Compare Share Share Today's Range$4.75▼$5.1250-Day Range$3.47▼$5.3252-Week Range$1.28▼$5.51Volume67,863 shsAverage Volume234,835 shsMarket Capitalization$284.19 millionP/E RatioN/ADividend YieldN/APrice Target$12.20 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Century Therapeutics alerts: Email Address Century Therapeutics MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.80 Rating ScoreUpside/Downside198.2% Upside$14.17 Price TargetShort InterestBearish8.71% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.54Based on 11 Articles This WeekInsider TradingSelling Shares$127,635 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($2.40) to ($1.42) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.09 out of 5 starsMedical Sector732nd out of 947 stocksBiological Products, Except Diagnostic Industry128th out of 159 stocks 3.4 Analyst's Opinion Consensus RatingCentury Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.83, and is based on 5 buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $14.17, Century Therapeutics has a forecasted upside of 198.2% from its current price of $4.75.Amount of Analyst CoverageCentury Therapeutics has only been the subject of 2 research reports in the past 90 days. Previous Next 2.0 Short Interest Percentage of Shares Shorted8.71% of the float of Century Therapeutics has been sold short.Short Interest Ratio / Days to CoverCentury Therapeutics has a short interest ratio ("days to cover") of 7.1.Change versus previous monthShort interest in Century Therapeutics has recently decreased by 3.31%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldCentury Therapeutics does not currently pay a dividend.Dividend GrowthCentury Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for IPSC. Previous Next 2.5 News and Social Media Coverage News SentimentCentury Therapeutics has a news sentiment score of 0.54. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 11 news articles for Century Therapeutics this week, compared to 1 article on an average week.Search InterestOnly 2 people have searched for IPSC on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat Follows3 people have added Century Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 50% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Century Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $127,635.00 in company stock.Percentage Held by InsidersOnly 7.60% of the stock of Century Therapeutics is held by insiders.Percentage Held by InstitutionsOnly 32.28% of the stock of Century Therapeutics is held by institutions. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Century Therapeutics are expected to grow in the coming year, from ($2.40) to ($1.42) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Century Therapeutics is -2.07, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Century Therapeutics is -2.07, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCentury Therapeutics has a P/B Ratio of 0.93. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Porter & CompanyMy next big prediction isn’t a predictionI believe this could change your life forever. I’m talking about transforming everything for you, financially. You see, a rare market anomaly has emerged that I believe is going to make some people very wealthy. Almost nobody in the mainstream media or Wall Street has connected the dots on what’s going on, but that ignorance won’t last for long. When they wake up to this situation, billions of dollars will flood in.Click here now to sign up About Century Therapeutics Stock (NASDAQ:IPSC)Century Therapeutics, Inc., a biotechnology company, develops transformative allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. The company's lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy targeting CD19 for relapsed, refractory B-cell lymphoma. It is also developing CNTY-102, a CAR-iT targeting CD19 + CD22 for relapsed, refractory B-cell lymphoma and other B-cell malignancies; CNTY-107, an iPSC-derived Nectin-4 CAR gamma delta T-cell therapy product candidate; CNTY-104, a CAR-iT or CAR-iNK multi-specific candidate for acute myeloid leukemia; and CNTY-106, a CAR-iNK or CAR-iT multi-specific candidate for multiple myeloma. Century Therapeutics, Inc. was incorporated in 2018 and is headquartered in Philadelphia, Pennsylvania.Read More IPSC Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart IPSC Stock News HeadlinesMarch 11, 2024 | insidertrades.comAdrienne Farid Sells 22,831 Shares of Century Therapeutics, Inc. (NASDAQ:IPSC) StockMarch 15, 2024 | markets.businessinsider.comBuy Rating Affirmed for Century Therapeutics on Strong Clinical and Financial OutlookMarch 18, 2024 | Paradigm Press (Ad)8,788% Return Predicted For THIS Crypto (already up 40% in 6 months)THIS cryptocurrency has gained 40% in 6 months. A crypto millionaire who has researched the space for a decade says it will go up 8,788% in 5 years. The name of this cryptocurrency is revealed right here: March 15, 2024 | finanznachrichten.deCentury Therapeutics, Inc.: Century Therapeutics Reports Full Year 2023 Financial Results and Provides Business UpdatesMarch 14, 2024 | investorplace.comIPSC Stock Earnings: Century Therapeutics Misses EPS, Misses Revenue for Q4 2023March 14, 2024 | benzinga.comCentury Therapeutics: Q4 Earnings InsightsMarch 14, 2024 | globenewswire.comCentury Therapeutics Reports Full Year 2023 Financial Results and Provides Business UpdatesMarch 11, 2024 | msn.comCentury Therapeutics to Showcase Groundbreaking Cancer Research at AACR Annual Meeting 2024March 18, 2024 | InvestorPlace (Ad)They said crypto was dead. It went up 100X.Bitcoin’s haters are out again. Despite the price doubling in the last six months alone… That hasn’t stopped the experts from piling on. Warren Buffett’s right-hand man Charlie Munger called crypto investors “idiots” in one of his last interviews. JPMorgan CEO Jamie Dimon, recently called Bitcoin a “pet rock” and “a hyped-up fraud.” But when it comes to cryptos, these are exactly the people you shouldn’t listen to. They’ve predicted crypto’s demise for years.March 9, 2024 | finance.yahoo.comCentury Therapeutics Inc (IPSC) COO Adrienne Farid Sells 53,515 SharesMarch 5, 2024 | globenewswire.comCentury Therapeutics Announces Six Upcoming Poster Presentations at the 2024 American Association for Cancer Research (AACR) Annual MeetingFebruary 22, 2024 | investorplace.com3 Millionaire-Maker Under-$10 Stocks to Buy in February 2024February 15, 2024 | seekingalpha.comIPSC Century Therapeutics, Inc.February 14, 2024 | investing.comCentury Therapeutics Inc (IPSC)February 1, 2024 | finance.yahoo.comCentury Therapeutics to Present at the Guggenheim Healthcare Talks 6th Annual Biotechnology ConferenceJanuary 22, 2024 | benzinga.comIN8bio's Phase 1 Clinical Trial Of INB-100 Offers Hope To Leukemia Patients With Promising DataDecember 13, 2023 | markets.businessinsider.comHold Rating on Century Therapeutics Amid Early Clinical Data and Market SpeculationDecember 9, 2023 | finance.yahoo.comCentury Therapeutics Presents Initial Data from CNTY-101 Phase 1 ELiPSE-1 Trial Supporting the Potential for a Multi-Dosing Strategy for CAR iNK Enabled by Allo-Evasion™ EditsDecember 8, 2023 | markets.businessinsider.comBuy Rating Affirmed for Century Therapeutics: Promising Clinical Data and Financial Stability Highlight PotentialDecember 7, 2023 | finance.yahoo.comCentury (IPSC) Up 36% on FDA Nod to Begin Phase I Lupus StudyDecember 7, 2023 | finance.yahoo.comCentury Therapeutics, Inc.'s (NASDAQ:IPSC) largest shareholders are public companies who were rewarded as market cap surged US$47m last weekDecember 6, 2023 | markets.businessinsider.comCentury Therapeutics Announces IND Application Clearance For CNTY-101December 6, 2023 | msn.comCentury Therapeutics stock gains after IND clearance for lupus candidateDecember 6, 2023 | finance.yahoo.comCentury Therapeutics to Host Conference Call to Discuss Preliminary Clinical Data from Phase 1 ELiPSE-1 trial of CNTY-101 in Relapsed or Refractory B-cell Lymphomas and Planned Phase 1 Study in Systemic Lupus ErythematosusDecember 6, 2023 | finance.yahoo.comCentury Therapeutics Receives FDA Clearance of IND Application for CNTY-101 in Systemic Lupus ErythematosusNovember 21, 2023 | finance.yahoo.comCentury Therapeutics to Present at the Piper Sandler 35th Annual Healthcare ConferenceNovember 15, 2023 | markets.businessinsider.comPromising Future for Century Therapeutics: Analyzing Daina Graybosch’s Buy Rating Amid Key Clinical Trials and Corporate DevelopmentsSee More Headlines Receive IPSC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Century Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/10/2021Today3/18/2024Next Earnings (Estimated)5/09/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:IPSC CUSIPN/A CIK1850119 Webwww.centurytx.com Phone267-817-5790FaxN/AEmployees163Year FoundedN/APrice Target and Rating Average Stock Price Target$14.17 High Stock Price Target$24.00 Low Stock Price Target$5.00 Potential Upside/Downside+156.8%Consensus RatingModerate Buy Rating Score (0-4)2.80 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)($2.29) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-130,930,000.00 Net Margins-6,115.12% Pretax Margin-5,071.34% Return on Equity-51.24% Return on Assets-30.00% Debt Debt-to-Equity RatioN/A Current Ratio8.50 Quick Ratio8.50 Sales & Book Value Annual Sales$2.23 million Price / Sales127.44 Cash FlowN/A Price / Cash FlowN/A Book Value$5.13 per share Price / Book0.93Miscellaneous Outstanding Shares59,830,000Free Float55,288,000Market Cap$284.19 million OptionableOptionable Beta1.29 5G Stocks: The Path Forward is ProfitableClick the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free Report Key ExecutivesDr. Adrienne Farid Ph.D. (Age 62)COO & Head of Early Development Comp: $650.66kMr. Brent Pfeiffenberger M.B.A.Pharm.D., CEO & DirectorMr. Douglas Carr CPAInterim Principal Financial Officer, Senior VP of Finance & Operations and SecretaryDr. Gregory Russotti Ph.D. (Age 57)Chief Technology & Manufacturing Officer Mr. Kenneth J. Dow J.D.Senior VP of General CounselDr. Shane Williams Ph.D.Chief People OfficerDr. Hyam I. Levitsky M.D. (Age 66)President of Research & Development Comp: $502.12kMichael Naso Ph.D.Senior VP of Cell EngineeringDr. Nick Trede M.D.Ph.D., Senior VP & Head of Clinical DevelopmentMore ExecutivesKey CompetitorsJasper TherapeuticsNASDAQ:JSPRMesoblastNASDAQ:MESOSutro BiopharmaNASDAQ:STROAgenusNASDAQ:AGENSOPHiA GENETICSNASDAQ:SOPHView All CompetitorsInsiders & InstitutionsVanguard Group Inc.Bought 5,483 shares on 3/11/2024Ownership: 1.880%Adrienne FaridSold 22,831 sharesTotal: $117,351.34 ($5.14/share)Goldman Sachs Group Inc.Sold 3,653 shares on 3/1/2024Ownership: 0.075%Abel Hall LLCBought 10,071 shares on 2/28/2024Ownership: 0.017%Virtu Financial LLCBought 14,018 shares on 2/26/2024Ownership: 0.023%View All Insider TransactionsView All Institutional Transactions IPSC Stock Analysis - Frequently Asked Questions Should I buy or sell Century Therapeutics stock right now? 6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Century Therapeutics in the last year. There are currently 1 hold rating and 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" IPSC shares. View IPSC analyst ratings or view top-rated stocks. What is Century Therapeutics' stock price target for 2024? 6 brokerages have issued 1-year price objectives for Century Therapeutics' shares. Their IPSC share price targets range from $5.00 to $24.00. On average, they expect the company's share price to reach $14.17 in the next year. This suggests a possible upside of 198.2% from the stock's current price. View analysts price targets for IPSC or view top-rated stocks among Wall Street analysts. How have IPSC shares performed in 2024? Century Therapeutics' stock was trading at $3.32 at the beginning of 2024. Since then, IPSC shares have increased by 43.1% and is now trading at $4.75. View the best growth stocks for 2024 here. When is Century Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024. View our IPSC earnings forecast. How were Century Therapeutics' earnings last quarter? Century Therapeutics, Inc. (NASDAQ:IPSC) released its quarterly earnings data on Wednesday, November, 10th. The company reported ($0.48) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.40) by $0.08. Century Therapeutics had a negative trailing twelve-month return on equity of 51.24% and a negative net margin of 6,115.12%. When did Century Therapeutics IPO? (IPSC) raised $201 million in an initial public offering on Friday, June 18th 2021. The company issued 10,600,000 shares at a price of $18.00-$20.00 per share. J.P. Morgan, BofA Securities, SVB Leerink and Piper Sandler acted as the underwriters for the IPO. Who are Century Therapeutics' major shareholders? Century Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional investors include Avidity Partners Management LP (2.26%), Vanguard Group Inc. (1.88%), Vanguard Group Inc. (1.88%), Federated Hermes Inc. (1.03%), Bridgeway Capital Management LLC (0.20%) and New York Life Investment Management LLC (0.17%). Insiders that own company stock include Adrienne Farid, Douglas Carr, Eli Casdin, Luis Borges and Versant Venture Capital Vi, L. View institutional ownership trends. How do I buy shares of Century Therapeutics? Shares of IPSC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:IPSC) was last updated on 3/18/2024 by MarketBeat.com Staff From Our PartnersCentral Bank Gold Heist In ProgressColonial Metals8,788% Return Predicted For THIS Crypto (already up 40% in 6 months)Paradigm PressLike Tiny Crypto Retirement FundsCrypto 101 MediaMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceSHOCKING Footage From Tesla Gigafactory In Austin, TexasInvestorPlaceDid you make $29,000 two days with AI options trades?Prosper Trading AcademyForget AI, Imperium Is Expected to Grow 320,00% in 3 YearsBanyan Hill PublishingThe world’s greatest investmentPorter & Company Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Century Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.